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Valproate (VPA) is an established teratogen with an estimated risk 
of 10% major congenital malformation (MCM) and up to 40% neuro-
developmental disorders including autistic traits and cognitive defi-
cits.1,2 The VPA MCM risk is influenced by dose and polypharmacy.3 
Foetal anticonvulsant syndrome (FACS) and VPA embryopathy are 
defined by developmental delay, attention deficits and intellectual 
disability (ID).4,5
In February 2018, the European Medicines Agency (EMA) rec-
ommended that VPA should only be used in women of childbear-
ing age if they have epilepsy that does not respond to other AEDs, 
and if they are enrolled in a pregnancy prevention programme 
(“PREVENT”). One month later, the Coordination Group for Mutual 
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-1h]uom7ĹValproate (VPA) is a known teratogen associated with greater risk of 
major congenital malformations and other neurodevelopmental sequelae than all 
other licensed antiepileptic medicines. To reduce the potential for VPA-related tera-
togenicity, the European Medicines Agency issued recommendations in 2018. Over 
two-thirds of women/girls with intellectual disability (ID) may have treatment-resist-
ant epilepsy that could benefit from VPA treatment.
blvĹThis investigation compared VPA prescribing practice for women/girls with ID 
between European countries, specifically evaluating the practice in the UK with that 
in other countries.
;|_o7vĹAn expert working group with representation from key stake-holding or-
ganizations developed a survey for dissemination to relevant professionals across 
Europe.
!;vѴ|vĹSeventy one responses were received (27 UK, 44 Europe). Clinicians in the 
UK were more likely to report that they are working to mandatory regulations com-
pared with European respondents (P = .015). European respondents were less likely 
to be aware of user-independent contraception options (P = .06). In The UK, VPA reg-
ulations were more likely to be applied to women with ID than in Europe (P = .024).
om1ѴvbomĹ There is heterogeneity in the application of VPA regulations across 
Europe for women/girls with ID. In both the UK and Europe, the regulations lack suit-
able adjustments for specific ID-related factors.
  + )  ! 	 "
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Recognition and Decentralised Procedures-Human (CMDh) en-
dorsed new measures to avoid in utero valproate exposure.6 In the 
UK, the Medicines and Healthcare products Regulatory Agency 
(MHRA) updated its VPA prescription regulations to contraindicate 
VPA use in women/girls of childbearing age without restrictions.7 
The UK regulations align with those proposed by the EMA.
ƐĺƐՊ|ՊbuѴvņol;mb|_bm|;ѴѴ;1|-Ѵ7bv-0bѴb|Ő	ő
Girls/women with ID require specific consideration. ID is com-
monly associated with comorbid epilepsy (22%), which is treat-
ment resistance in over two-thirds of cases.8 In terms of seizure 
control, VPA remains the drug of first choice for generalized epi-
lepsy.9 It has been shown to be effective in people with ID.10 A 
recent survey suggests a mean 30%-40% deterioration in seizure 
control when patients are changed from VPA to alternatives.11 
VPA also conveys mood stabilizing properties, which are par-
ticularly relevant in those with ID given the high prevalence of 
psychiatric comorbidities in this population.12 A recent UK inves-
tigation examining the implementation of the MHRA statement at 
a tertiary epilepsy centre (N = 125) found that over one-third of 
women using VPA had an ID, and one-fifth could not consent to a 
sexual relationship. In one in three patients, VPA treatment did not 
comply with the MHRA regulations.13
The aim of this study was to gain an understanding of how mea-
sures to restrict VPA in girls/women of childbearing age with ID have 
been implemented and regulated in clinical practice across Europe. 
The investigation will compare VPA prescribing between Europe and 
the UK.
ƑՊ |Պ$	"
A working group was assembled comprising of expert members from 
the Faculty of Psychiatry of Intellectual Disability of the Royal College 
of Psychiatrists (RCPsych) (RS, KC and LW), International League 
against Epilepsy (ILAE) (MR), European Psychiatric Association, 
Mental Health in Intellectual Disability (EPA-MHID) Section (BP), 
European Association for Mental Health In Intellectual Disability 
(EAMHID) (RB), Association of British Neurologists (ABN) (HAL), and 
representation from INFACT (Independent Foetal Anticonvulsant 
Trust) and FACS Association (EM).
The STROBE checklist was used to guide reporting of this 
cross-sectional study. An initial draft questionnaire was prepared 
(LW) and refined by the working group over three rounds of con-
sultations using a Delphi method. The finalized survey was sent 
electronically to key members of different stake-holding organi-
zations across the UK and Europe for distribution among other 
members.
The survey questions focused on specific aspects of the current 
regulations governing VPA use and how these were applied to girls/
women with ID of childbearing age (Supplementary Information 1). 
The survey results were analysed as a whole and findings also com-
pared between the UK and other European countries. Content 
analysis of the qualitative data was performed to identify themes. 
The z-score test was used to compare UK with other European re-
sponses, with a two-tailed hypothesis and significance accepted at 
P < .05. This study included European countries expected to take 
account of the EMA statement, even if they were not part of the 
European Union.
ƑĺƐՊ|Պ|_b1v
Participants were advised that participation was voluntary and that 
responses would be anonymized and analysed. No identifiable data 
were collected. Consent was implicit by participation.
ƒՊ |Պ!"&$"
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A total of 71 respondents representing 17 countries from a wide 
range of clinical specialties (Supplementary Information 2) re-
sponded. Twenty-seven of the 71 respondents were based in the 
UK. The majority of respondents (93%) work with girls or women 
with ID. VPA was prescribed for epilepsy (79%), bipolar affective 
disorder (51%), migraine (7%) or other psychiatric/behavioural pres-
entations (9%).
ƒĺƑՊ|Պ&1olr-u;7b|_uor;
ƒĺƑĺƐՊ|Պ -m|b|-|b;7-|-
The interpretation of regulations varies considerably between clini-
cians working in the UK and those working in other European coun-
tries (Table 1/Figure 1). A significantly higher proportion of UK-based 
clinicians reported they were working to mandatory regulations than 
in the other European countries, suggesting lower awareness levels 
of VPA-related regulations among European respondents or more 
flexible interpretation of the regulations. In this context, “manda-
tory” means “legally binding” (ie if mandatory prescribing rules are 
not followed, the medication is essentially used off-licence and with-
out the usual medicolegal protections provided by the licensed use 
of the drug). In Europe, over one-third of clinicians were not aware of 
formal recommendations on user-independent contraception. This 
suggests that specific advice on highly reliable contraception may 
be offered less often in other European countries compared with 
the UK.
Self-reported compliance with regulations in women and girls 
with ID was greater in the UK compared with Europe. However, in 
both the UK and other European countries the majority of respon-
dents (71%) reported a lack of specific guidance for prescribing VPA 
ՊՍ Պ |ՊƒWATKINS ET AL.
to girls or women with ID who are not sexually active with no differ-
ence between the UK and Europe.
In the UK, clinicians were more likely to report having access to 
patient information resources but “easy-read” patient information 
was no more likely to be available in the UK than other European 
countries.
ƒĺƑĺƑՊ|Պ -Ѵb|-|b;7-|-
Across European countries, 41% of respondents stated that they were 
working in regions without mandatory VPA prescribing regulation 
for women and girls of childbearing age and 32% of respondents 
stated the prescribing guidelines that are in place for women are 
not followed in practice (Supplementary Information 2). A themed 
content analysis of free comment responses identified three distinct 
categories that suggest reasons for this lack of adherence.
Reasons for lack of adherence to VPA regulation: 
1. Knowledge—there is a general lack of awareness of VPA reg-
ulations, more specifically regarding mental capacity, informed 
consent and how to assess more complex scenarios.
2. Treatment factors—clinicians and/or patients are hesitant to 
change effective AED treatment, particularly if it has been 
-u-l;|;u
$o|-Ѵv-lrѴ;
Őm=ƕƐőŖŖ & uor; P-Ѵ;
Awareness of VPA regulations 63/70 25/27 37/43 .4009
Recommendation of acceptable forms of 
contraception
45/63 21/25 23/37 .06
Mandatory regulation in place 44/62 22/25 22/37 .015*
Guidance followed in clinical practice 47/63 21/25 26/38 .164
Applied to women and girls with ID 54/61 24/24 30/37 .024*
Specific guidance for women with ID who 
are not sexually active
18/63 9/25 9/38 .29
Patient information resources available 56/70 25/27 31/43 .037*
Patient information available in easy-read 
format
37/68 17/25 23/43 .24
*Significance at 0.05. 
**Number of total respondents may differ as not all questions were answered. 
$     Ɛ Պ Comparison of respondents' 
views between UK and Europe
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difficult to achieve treatment success. The balance of risk is mul-
tifactorial and often based on a limited evidence base. For some, 
there may be a lack of suitable alternative treatments either be-
cause of previous failure, side effects, or due to access and finan-
cial constraints.
3. Ethical considerations—patient choice is often not considered 
within regulations, whether an individual can provide informed 
consent or not. Contraception advice may be inappropriate for 
people who are not sexually active, particularly girls/women with 
ID who may lack the mental capacity to consent to sexual activity.
European respondents consider a wide range of exceptional 
circumstances in which the prescription of VPA is necessary and 
appropriate in this population (Table 2). The exceptional scenarios 
raised are consistent with the expert opinion consensus amalgam-
ated in the UK.14
ƓՊ |Պ	"&""
The survey results demonstrate heterogeneous interpretation, regu-
lation and implementation of VPA EMA guidelines for childbearing-
age girls/women across Europe.
The regulations described in the responses from across Europe 
can be classified into four categories, with category 3 being the most 
common and consistent with the EMA and UK-MHRA regulations.
Categories (1-4) of VPA regulation currently in place around 
Europe based on clinician feedback.
1. No guidanceunaware of EMA warning
2. No guidanceaware of EMA warning
3. Do not prescribe for girls or women of childbearing age with excep-
tions and restrictions
4. Do not prescribe for girls or women of childbearing age without 
exception
Regulation adherence appears more rigid in the UK than in 
Europe. However, in the UK, clinicians still lack a clear understand-
ing of the regulations, which make no specific reference to patients 
with ID. Not all UK respondents were aware that the regulations are 
mandatory; some (9/25) stated there is specific guidance for peo-
ple with ID who are not sexually active, although this is not actually 
included in the regulation. For those not sexually active because of 
their disabilities, participation in a user-independent contraceptive 
programme could add unnecessary risk and lead to emotional dis-
tress to both individuals and their families. In Europe, a proportion 
of clinicians reported that, where regulation is in place, it may not be 
followed, particularly for women with ID. Specifically, there is a lack 
of understanding of mental capacity assessment.
The EMA recommendations lack consideration of specific ID–re-
lated factors including the following: individuals who lack the men-
tal capacity to provide informed consent to sexual relationships; 
ooѴ;7uor;-mu;vrom7;m|vŝb;v=uol;r;ub;m1; u;1oll;m7-|bomv
Exceptional circumstances Exceptional circumstances
 Life-threatening situations, for example status 
epilepticus.
 Patient choice with valid informed consent with 
pregnancy prevention.
 Patient choice with valid informed consent without 
pregnancy prevention.
 Women who lack the capacity to consent to sexual 
relationships
 Treatment failure with other AEDs.
 Intolerable side effects from other AEDs.
 Specialist choice as most appropriate treatment 
given clinical scenario balancing risk and outcomes.
 Alternative treatments are not 
suitable, specialist consultation 
required
Restrictions Restrictions
 Teratogenic risk must be discussed
 Pregnancy test prior to prescribing
 Adherence to appropriate contraceptive regime 
(user-independent)
 Do not consider VPA for anything other than 
epilepsy (eg Bipolar affective disorder)
 Any women prescribed to be placed on a register
 u;]m-m1ru;;m|bomruo]u-ll;
a. assessment of pregnancy 
potential
b. pregnancy tests before and 
during treatment as needed
c. Counselling on risks of 
VPA and need for effective 
contraception during treatment
d. annual review with specialist
e. risk acknowledgement form
 Educational materials
 Alert card
 No prescribing for migraine or 
bipolar during pregnancy
$     Ƒ Պ Comparison between EMA 
recommendations and exceptional 
circumstances and prescribing restrictions 
pooled from European responses
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individuals who are not sexually active; and easy-read/accessible in-
formation. The same deficits are apparent in the UK regulations.15
ƓĺƐՊ|Պblb|-|bomv
The survey response rate was low considering the number of poten-
tial responders. Information derived from a single respondent may 
not have been representative and therefore could be biased towards 
the views of those with an interest in this field. The discussion of 
European results is based upon respondents’ views in practice and 
not a review of regulations.
The results of this survey demonstrate heterogeneity in the ap-
plication of VPA regulations across Europe for women/girls with ID. 
In both the UK and Europe, the regulations lack suitable adjustments 
for specific ID–related factors. From these findings, we conclude 
that improvements are needed in four areas to optimize the safe use 
of VPA in women with ID and epilepsy.
Recommendations for women/girls of childbearing age with ID
1. 71-|bom—increase clinician awareness, develop knowledge and 
improve regulation adherence.
2. !;]Ѵ-|bomv—explicit exceptional circumstances where VPA may 
be appropriate should be identified. Provide clear guidance/path-
ways on switching from VPA to alternatives and how decisions for 
individuals with ID should be considered.
3. "u;bѴѴ-m1;Ōestablishes national VPA registers for all VPA child-
bearing women/girls.
4. "_-u;7 7;1bvbomŊl-hbm]Ōarrangements at local level for deci-
sion-making to involve the patient or patient representative. The 
clinical decision-maker should have sufficient expertise to weigh 
up the risks and benefits of VPA treatment and use of safe con-
traception using accessible information, including documents in 
easy-read format to facilitate patient participation in decision-
making (Table 3).
)	 $"
None.
;;Ѵo=	 bѴ7Ő-|_-Ɛő
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Valproate 
prescribing
Assessment of capacity to provide 
informed consent to AED treatment
Unable to provide informed 
consent to AED treatment 
and therefore prescribed in 
best interests, potentially 
involving patient advocate/ 
representative.
Information 
sharing
Risks and benefits of VPA prescription for 
individual and unborn child.
Unborn child: 10% risk of MCM’s, up to 
40% risk of neurodevelopmental and 
cognitive sequelae of varying degree. 
Risks dose-dependent and increased with 
polypharmacy.
Risk to individual: common side effects 
include weight gain, tremor and rarely 
polycystic ovary syndrome. Risk is higher 
with higher dose.
Risk of stopping medication: increased 
seizure frequency, injury, hospitalization, 
SUDEP and serious harm to unborn child 
if pregnant.
Information should be shared 
as suitable to the cognitive 
and communication needs 
of the individual to help 
support understanding. This 
will be guided by the person 
and those close to them 
(family/carers).
Support may include longer 
appointments, easy-
read documentation or 
involvement from other 
healthcare professionals 
with specialist ID expertise.
Contraceptive 
advice
Capacity to consent to sexual relationships 
and sexually active/or the possibility of 
becoming sexually active
If yes, for further discussion around the 
“Prevent” programme.
User-independent contraception, some of 
which are invasive
If no, move to follow Pathway 2.
Unable to provide informed 
consent to sexual 
relationship
No need for further 
discussion around 
contraception and sexual 
relationships that could 
cause distress.
Outcome Risk acknowledgement form to be signed 
by epilepsy service and individual, 
enrolment in “Prevent,” minimum annual 
review with a specialist
Risk acknowledgement form 
to be completed, opting out 
of “Prevent” programme
$     ƒ Պ Valproate shared decision-
making tool—Girls/women with ID
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